What is the recommended treatment for low serum iron, low transferrin, and low ferritin?

Treatment for Severe Iron Deficiency

Based on your laboratory values showing severe iron deficiency (ferritin 4.56 ng/mL, serum iron 11, transferrin 3), you should initiate iron replacement therapy immediately, with intravenous iron being the preferred route if there are any comorbidities, ongoing blood loss, malabsorption issues, or need for rapid repletion. 1

Diagnostic Interpretation

Your laboratory results indicate severe absolute iron deficiency:

• Ferritin 4.56 ng/mL is critically low (goal is ≥50 ng/mL in the absence of inflammation) 1
• Low serum iron and transferrin suggest depleted iron stores with inadequate iron transport capacity 2
• These values meet criteria for iron deficiency regardless of hemoglobin status 2, 3

Treatment Algorithm

First-Line Considerations

Oral iron therapy is typically first-line for uncomplicated iron deficiency:

• Ferrous sulfate 325 mg daily or on alternate days (alternate-day dosing may improve absorption and reduce side effects) 2
• Preparations containing 28-50 mg elemental iron are reasonable to minimize gastrointestinal side effects 4
• Reassess laboratory parameters (CBC, ferritin, transferrin saturation) at 8-10 weeks 4

Indications for Intravenous Iron (Preferred Route)

Intravenous iron should be strongly considered if any of the following apply 1, 2:

• Oral iron intolerance (gastrointestinal symptoms occur in ~40-60% of patients) 5
• Malabsorption conditions: celiac disease, atrophic gastritis, post-bariatric surgery, inflammatory bowel disease 1, 2
• Ongoing blood loss: heavy menstrual bleeding, gastrointestinal bleeding, angiodysplasia 1
• Chronic inflammatory conditions: chronic kidney disease, heart failure, inflammatory bowel disease, cancer 6, 2
• Pregnancy (second and third trimesters) 2
• Need for rapid iron repletion (severe symptomatic anemia) 7
• Inadequate response to oral iron after 8-10 weeks 5

Intravenous Iron Formulations

If IV iron is indicated, ferric derisomaltose (FDI) is the only FDA-approved formulation for total dose infusion 1:

• Dose: 1000 mg infusion or up to 20 mg/kg (not exceeding 1500 mg) 1
• Dilute in 100 mL normal saline, infuse over 20-30 minutes 1
• FDI demonstrated cardiovascular mortality benefit in heart failure patients with iron deficiency 1

Alternative IV formulations include ferric carboxymaltose (FCM) and iron sucrose, all with comparable safety and efficacy 1

Critical Next Steps

Identify and Treat Underlying Cause

You must investigate the etiology of iron deficiency 2:

• Gastrointestinal evaluation (upper and lower endoscopy) if no obvious source identified, particularly in men and postmenopausal women 6
• Menstrual history in premenopausal women 2
• Screen for malabsorption disorders: celiac disease, atrophic gastritis, H. pylori infection 7
• Review medications: NSAIDs, anticoagulants, antiplatelet agents 2
• Assess for chronic inflammatory conditions: CKD, heart failure, IBD, cancer 6, 2

Monitoring Parameters

Laboratory reassessment at 4-8 weeks post-treatment 1:

• CBC with hemoglobin (expect 1-2 g/dL increase within 4-8 weeks) 1
• Ferritin (target ≥50 ng/mL without inflammation) 1
• Transferrin saturation (TSAT) calculated as serum iron/TIBC × 100 (target ≥20%) 1
• Do not check iron parameters within 4 weeks of IV iron as circulating iron interferes with assays 1

TSAT <20% has high sensitivity for diagnosing iron deficiency and is particularly useful when ferritin is unreliable due to inflammation 1, 8, 9

Important Caveats

Frequency of Repeat Dosing

• Single dose may suffice if underlying cause is eliminated 1
• Ongoing losses require repeated administrations: frequency depends on degree of blood loss or malabsorption 1
• Patients with recurrent blood loss need more aggressive monitoring even without anemia, as non-anemic iron deficiency causes clinical complications 1

Potential Complications of IV Iron

Monitor for 1, 7:

• Acute infusion reactions (mild reactions in ~13% of patients) 5
• Hypophosphatemia/osteomalacia with repeated high-dose infusions 7
• Iron overload (avoid if ferritin >500-800 ng/mL depending on condition) 3

Special Populations

In chronic kidney disease: ferritin targets differ (≤100 μg/L for predialysis/peritoneal dialysis, ≤200 μg/L for hemodialysis patients) 6

In heart failure: TSAT and serum iron levels correlate more strongly with functional capacity and outcomes than ferritin 8, 9

In inflammatory conditions: ferritin may be falsely elevated; rely more heavily on TSAT <20% for diagnosis 1, 6